Russian government's 'Pharma 2020 plan' to stimulate generics growth and GMP production across the country
AMSTERDAM, May 31, 2013 /CNW/ - CPhI Russia reflected growth in the Russian Pharma market at its debut next to IPhEB, the St Petersburg International Forum for Pharmacy, Medical Equipment, Biotechnology and Radiology, and is the latest addition to UBM Live's global pharmaceutical events portfolio. The event was held at the Manege Central Exhibition Hall, St Petersburg on 10th and 11th of April 2013 and brought together senior Russian pharma professionals and international pharmaceutical suppliers and buyers.
Following the event, the next few years are predicted to be a very exciting time for investing in the region as the Russian pharmaceutical market is now considered to be one of the most dynamic in the world, and continues to grow at an average of 10-12% per year. The country is already the eleventh largest pharmaceutical market and is projected to reach a value of US $26.7 billion by the end of this year. Furthermore, this tremendous growth is being achieved thanks to the government support through its ambitious "Pharma 2020 Plan", introduced in October 2009. The programme is aimed at achieving a complex structural upgrade of the national pharmaceutical industry by means of a substantial improvement in production capacity - increasing both domestic and export production. The Plan, outlined alongside other pharmaceutical innovations at the event, is currently in its second stage and on course to achieve the following goals by 2017:
- Home production of national generics and achievement of medicines independence of the Russian Federation
- Accreditation of all foreign producers of pharmaceutical substances and official medicines entering the Russia market by the regulatory bodies in order to strengthen quality control for official medicines
- Establishment of joint manufacturing and R&D structures with production sites on the territory of Russia
Another Pharma 2020 project is the development of new, and the modification of existing training programs, intended to provide the pharma industry with employees capable of ensuring the transition to international GMP standards.
"The Russian Government is making a big effort to keep the pharmaceutical market attractive for international manufacturers in order for them to fulfil their localisation plans" said Andrew Pert, Brand Director for CPhI Russia. "The harmonisation with GMP is a mandatory step for the Russian government and it has to be achieved as soon as possible to enable the national market to be competitive and to play an active role within the international pharmaceutical market - but the growth potential in this region's industry should not be under estimated and we envisage this event will expand enormously over the coming years."
In addition to the exhibition, CPhI Russia presented an in-depth conference programme that provided a comprehensive picture of the Russian pharmaceutical market.
The plenary session, entitled "Pharmaceutical and Medical Industries as Strategic areas of Innovative Economic Development" focused on the Russian economic strategy in a rapidly growing pharmaceutical market, particularly on how innovation and improved GMP standards and harmonisation can stimulate rapid growth. Furthermore, a debate on the International Cooperation in the area of pharmaceuticals and biotechnology, followed by the successful experiences of international pharmaceutical companies provided unparalleled insights into how companies can enter and succeed in this most dynamic of markets, including opportunities in the fast developing generics and biosimilars market and the implications this has for a regional regulatory framework.
With 1,853 requests and 437 meetings conducted, the "Matchmaking programme" was a huge success, allowing participants to arrange one-to-one meetings with potential business partners prior to attending the event via an automated meeting scheduler.
Additionally, the Gala Awards night for "Russian Leaders in the Pharmaceutical and Biotechnology Industry", sponsored by Sotex Pharm, took place during the opening ceremony. The awards were designed to encourage the development of cutting-edge achievements in the field of pharmaceutical, biotechnological and medical technologies and winners included:
- OAO Phamasyntez - a leader in innovative TB drugs - for its 'contribution to the development of innovative Russian products'
- OAO Akrikhin for its 'contribution to the modernisation of the pharma industry in Russia'
- Regina Ilyasovna, general director of Invar pharmaceuticals, in the category of 'effective business strategy' for developing successful business partnering relations with a number of European pharmaceutical companies
- OJSC Biosintez for the 'development of export potential in the Russian pharmaceutical industry' by meeting GMP requirements in order to improve the export potential of Russian Pharmaceutical companies
- Indukern-Rus LLC, in the category of 'most reliable partner'
CPhI Russia 2014 expands to facilitate Pharma 2020 plan:
16th-17th April 2014, Lenexpo, St. Petersburg, Russia.
Russia's Pharma 2020 plan, which calls for 90% of medicines to be locally produced by 2020, will require a substantial increase in the country's entire pharmaceutical supply chain. In response to this, to help provide a central hub for the growing demand, CPhI Russia 2014 will also launch four new co-located events:
- ICSE- connecting the pharmaceutical community with outsourcing solution providers, offering a forum for business development, networking and education
- P-MEC- delivering innovative pharmaceutical machinery, equipment and technology
- InnoPack- bringing together buyers and specifiers from the packaging and pharmaceutical industries
MEDTEC Russia/iMeR - Leading suppliers of the international medical manufacturing device industry
Notes for Editors
CPhI drives growth and innovation at every step of the global pharmaceutical supply chain from drug discovery to finished dosage. Through exhibitions, conferences and online communities, CPhI brings together more than 100,000 pharmaceutical professionals each year to network, identify business opportunities and expand the global market. The flagship event, CPhI Worldwide is held in Europe, with additional events in China, India, Japan, Southeast Asia, Russia and South America co-located with ICSE for contract services, P-MEC for equipment, InnoPack for packaging and BioPh for biopharma. CPhI provides an online buyer & supplier directory at CPhI-Online.com and hosts a global community with news and analysis at PharmaEvolution.com, produced by UBM Live and partners.
For more information visit: http://www.cphi.com
About UBM Live
UBM Live connects people and creates opportunities for companies across five continents to develop new business, meet customers, launch new products, promote their brands, and expand their market. Through premier brands such as TFM&A, Internet World, IFSEC, MD&M, CPhI, Cruise Shipping Miami, the Concrete Show, and many others, UBM Live exhibitions, conferences, awards programs, publications, Websites, and training and certification programs are an integral part of the marketing plans of companies across more than 20 industry sectors.
About RESTEC® Exhibition Company:
RESTEC® Exhibition Company is one of the top three leaders of the Russia`s exhibition business. The optimal structure formed by RESTEC® let us combine exhibition, congress, business and contest programs that altogether foster effective work of our exhibitors, participants, delegates and trade visitors. At this point our exhibition and congress events continue developing as centers of international business networking with the constantly growing number of countries and participants represented. For more information, go to http://www.restec.ru/en
SOURCE: UBM Live
For further information:
RESTEC® Exhibition Company, St. Petersburg,